Game Creek Capital LP raised its position in shares of CVS Health Corp (NYSE:CVS) by 50.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,000 shares of the pharmacy operator’s stock after purchasing an additional 5,000 shares during the quarter. Game Creek Capital LP’s holdings in CVS Health were worth $983,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Brookmont Capital Management grew its stake in shares of CVS Health by 3.0% in the fourth quarter. Brookmont Capital Management now owns 5,184 shares of the pharmacy operator’s stock worth $340,000 after acquiring an additional 152 shares during the period. Avestar Capital LLC grew its stake in shares of CVS Health by 19.6% in the fourth quarter. Avestar Capital LLC now owns 951 shares of the pharmacy operator’s stock worth $57,000 after acquiring an additional 156 shares during the period. Clarus Wealth Advisors grew its stake in shares of CVS Health by 6.9% in the fourth quarter. Clarus Wealth Advisors now owns 2,456 shares of the pharmacy operator’s stock worth $161,000 after acquiring an additional 158 shares during the period. Griffin Asset Management Inc. grew its stake in shares of CVS Health by 1.4% in the third quarter. Griffin Asset Management Inc. now owns 11,438 shares of the pharmacy operator’s stock worth $900,000 after acquiring an additional 160 shares during the period. Finally, Adviser Investments LLC grew its stake in shares of CVS Health by 5.4% in the fourth quarter. Adviser Investments LLC now owns 3,163 shares of the pharmacy operator’s stock worth $207,000 after acquiring an additional 162 shares during the period. Institutional investors and hedge funds own 81.55% of the company’s stock.
CVS opened at $54.22 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.65 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $68.57 billion, a P/E ratio of 7.50, a price-to-earnings-growth ratio of 1.04 and a beta of 0.94. CVS Health Corp has a 12-month low of $51.77 and a 12-month high of $82.15.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 3rd. Investors of record on Tuesday, April 23rd will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.69%. The ex-dividend date of this dividend is Monday, April 22nd. CVS Health’s payout ratio is 28.25%.
In other CVS Health news, insider Larry J. Merlo sold 166,368 shares of CVS Health stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $64.51, for a total transaction of $10,732,399.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP James David Clark sold 1,664 shares of CVS Health stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $58.14, for a total transaction of $96,744.96. Following the transaction, the senior vice president now directly owns 8,557 shares in the company, valued at approximately $497,503.98. The disclosure for this sale can be found here. In the last three months, insiders purchased 23,600 shares of company stock worth $1,270,896 and sold 245,671 shares worth $15,839,966. Company insiders own 0.53% of the company’s stock.
A number of brokerages have recently commented on CVS. Morgan Stanley set a $92.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research note on Friday, February 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $80.00 price target on shares of CVS Health in a research note on Thursday, February 21st. Barclays began coverage on shares of CVS Health in a research note on Tuesday, December 18th. They issued an “overweight” rating and a $91.00 price target for the company. BMO Capital Markets began coverage on shares of CVS Health in a research note on Wednesday, April 10th. They issued an “outperform” rating and a $58.00 price target for the company. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $91.00 price target on shares of CVS Health in a research note on Thursday, February 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company. CVS Health has an average rating of “Buy” and an average price target of $79.61.
COPYRIGHT VIOLATION NOTICE: “Game Creek Capital LP Has $983,000 Holdings in CVS Health Corp (CVS)” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/4296155/game-creek-capital-lp-has-983000-holdings-in-cvs-health-corp-cvs.html.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.